CVS Health price target raised to $89 from $82 at Morgan Stanley

Morgan Stanley analyst Erin Wright raised the firm’s price target on CVS Health (CVS) to $89 from $82 and keeps an Overweight rating on the shares. Last week’s Stars results were “encouraging” for the sector and Managed Care Organization sentiment has “improved slightly,” but there is “still a lot to prove” as the focus turns to utilization and early reads on 2026, the analyst tells investors in a Q3 earnings preview for the group.